Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows

v3.19.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2019
Sep. 30, 2018
Operating activities    
Net loss $ (40,955) $ (33,824)
Adjustments to reconcile net loss to net cash (used in) provided by operating activities:    
Depreciation and amortization 3,560 3,404
Accretion of discount on marketable securities (1,328) (166)
Stock-based compensation 7,629 802
Change in estimated fair value of the liability attributable to a research, development and commercialization agreement (119) 0
Revaluation of redeemable convertible preferred stock warrant liability 0 (839)
Loss on disposal of property and equipment 295 35
Other 82 307
Changes in operating assets and liabilities:    
Accounts receivable (5,042) (819)
Prepaid expenses and other assets 92 (901)
Accounts payable 1,477 (135)
Accrued compensation (1,589) 446
Other liabilities (180) 1,097
Deferred rent (42) 45
Deferred revenue (15,747) 49,166
Net cash (used in) provided by operating activities (51,867) 18,618
Investing activities    
Purchases of marketable securities (191,717) (81,456)
Maturities of marketable securities 114,076 0
Sales of marketable securities 20,000 0
Purchases of property and equipment (1,432) (759)
Net cash used in investing activities (59,073) (82,215)
Financing activities    
Payment of deferred offering costs 0 (2,413)
Payments of debt (3,500) 0
Proceeds from payment of note receivable by stockholder 0 208
Proceeds from exercise of common stock options and warrants 133 396
Taxes paid related to net share settlement of restricted stock units (297) 0
Proceeds from employee stock purchase plan 1,260 0
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 84,739
Net cash (used in) provided by financing activities (2,404) 82,930
Net (decrease) increase in cash, cash equivalents and restricted cash (113,344) 19,333
Cash, cash equivalents and restricted cash at beginning of period 125,313 22,035
Cash, cash equivalents and restricted cash at end of period 11,969 41,368
Supplemental disclosure of cash flow information:    
Cash paid for interest 898 942
Supplemental disclosure of non-cash investing and financing information:    
Purchase of property and equipment included in accounts payable 11 610
Deferred initial public offering costs included in accounts payable 0 1,659
Embedded interest associated with program fees $ 2,477 $ 0